Colorectal CancerPhase 3MORANCT02273167
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.
A Phase 3 study testing NER1006, 2-Day Split-Dosing, NER1006,1-Day Morning Split-Dosing and MOVIPREP, 2-Day Split-Dosing in people with Colorectal Cancer and Colorectal Carcinoma, run by Norgine at 29 sites in 7 countries.
Trial summary
This study evaluates the efficacy, safety and tolerability of NER1006 versus MOVIPREP in adult patients requiring bowel cleansing prior to any procedure that requires a clean bowel, using a 2-Day evening/morning Split-Dosing and 1-Day morning only Split-Dosing regimens. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Colorectal Cancer, Colorectal Carcinoma, Colon Cleansing
- What is being tested?
- NER1006, 2-Day Split-Dosing, NER1006,1-Day Morning Split-Dosing and MOVIPREP, 2-Day Split-Dosing
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 849 participants
- Where
- 29 sitesin 7 countries
- Study dates
- Oct 2014to Aug 2015
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must provide written informed consent.
- Male and female outpatients and inpatients aged: ≥18 to ≤85 years undergoing a screening, surveillance or diagnostic colonoscopy.
- Females of child-bearing potential must have a negative pregnancy test at Screening and at Visit 2 and must be practising one of the following methods of birth control and agree to continue with the regimen throughout the study period (unless postmenopausal or surgically sterile, or whose sole sexual partner has had a successful vasectomy): Oral, implantable, or injectable contraceptives (for a minimum of three months before study entry) in combination with a condom; Intrauterine device in combination with a condom; Double barrier method (condom* and occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam/gel/film/cream/suppository).
- Willing and able to complete the entire study and to comply with instructions.
Who cannot join
- Patients with past history within last 12 months or current episode of severe constipation (requiring repeated use of laxatives/enema or physical intervention before resolution), known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.
- Patients with ongoing severe acute Inflammatory Bowel Disease.
- Patients who have had previous significant gastrointestinal surgeries, including colonic resection, sub-total colectomy, abdomino-perineal resection, de-functioning colostomy, Hartmann's procedure and de-functioning ileostomy or other similar surgeries involving structure and function of the small or large colon.
- Regular use of laxatives or colon motility altering drugs in the last month (i.e. more than 2-3 times per week) and/or laxative use within 72 hours prior to administration of the preparation.
- Patients with active intestinal bleeding episodes or with a clinically significant low hemoglobin level <9 g/dL for women and <11 g/dL for men at screening.
- Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Show all 24Show fewer
- Known phenylketonuria.
- Known hypersensitivity to polyethylene glycols, ascorbic acid and sulfates (not including sulfa-based products) or any other component of the study drug or comparator
- Past history within the last 12 months or evidence of any on-going clinically relevant electrocardiogram (ECG) abnormalities (e.g. arrhythmias).
- History of uncontrolled hypertension with systolic blood pressure >170 mmHg and diastolic blood pressure >100 mmHg.
- Patients with cardiac insufficiency NYHA grades III or IV.
- Patients with severe renal insufficiency (i.e. with GFR, <30 mL/min/1.73m2).
- Patient with serum albumin <3.4 g/dL.
- Patients with liver disease of grades B and C according to the Child Pugh classification.
- Patients suffering from dehydration at screening as evaluated by the Investigator from physical examination and laboratory investigations.
- Patients with clinically significant electrolyte abnormalities, whether pre-existing or noted at screening, such as hypernatremia, hyponatremia, hyperphosphatemia, hypermagnesemia, hypokalemia, hypocalcaemia dehydration, or those secondary to the use of diuretics or angiotensin converting enzyme (ACE) inhibitors.
- Patients with any other clinically significant hematological parameters including coagulation profile at screening.
- Patients with impaired consciousness that might predispose them to pulmonary aspiration.
- Patients undergoing colonoscopy for foreign body removal and/or decompression.
- Patients who are pregnant or lactating, or intending to become pregnant during the study.
- Clinically relevant findings on physical examination based on the Investigator's judgment.
- History of drug or alcohol abuse within the 12 months prior to dosing.
- Concurrent participation in an investigational drug or device study or participation within three months of study entry.
- Patients who are ordered to live in an institution on court or authority order
Trial locations and contacts
29 sites in 7 countries.
29 sites in 7 countries
Poland6 sites
Uniwersytecki Szpital Kliniczny w Bialymstoku
Bialystok
Gabinet Internistyczny dr n. med. Krzysztof Janik
Częstochowa
NZOZ Centrum Medyczne-Szpital Swietej Rodziny
Lodz
Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych
Warsaw
Robert Petryka Gabinet Internistyczny
Warsaw
Lexmedica Durbajlo Hanna
Wroclaw
Italy5 sites
A.O.U. di Bologna - Policlinico S. Orsola-Malpighi
Bologna
Ospedale Valduce U.O. Gastroenterologia e Endoscopia
Como
P.O. Maresca OORR Area Vesuviana ASL
Naples
Centro di Riferimento Oncologico (C.R.O.) S.O.C Gastroenterologia
Pordenone
Pol. Univ. A. Gemelli U.O. di Endoscopia Digestiva Chirurgica
Roma
Spain5 sites
Hospital General Universitario de Alicante
Alicante
Hospital del Mar
Barcelona
Hospital Universitari Germans Trias i Pujol
Barcelona
Hospital Clínico San Carlos
Madrid
Hospital Ramon y Cajal - Ctra. De Colmenar km. 9, 100
Madrid
Belgium4 sites
AZ Sint-Lucas
Bruges
UZ Ghent
Ghent
UZ Leuven
Leuven, 3000 Leuven
CHC- Clinique Saint-Joseph
Liège
United Kingdom4 sites
Lothian Health Board
Edinburgh
Borders General Hospital
Melrose
Royal Shrewsbury Hospital
Shrewsbury
Royal Albert Edward Infirmary Department
Wigan
Germany3 sites
Kliniken Essen-Mitte; Abteilung für Gastroenterologie
Essen
Klinikum der Friedrich Schiller Universität Jena
Jena
Praxis für Innere Medizin, Gastroenterologie und Allg. Medizin
Ludwigshafen
France2 sites
Hôpital Avicenne- Service de Gastro-Entérologie
Bobigny
Hôpital Hotel-Dieu
Nantes
About this study
Official title: A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) Versus MOVIPREP Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.
This study evaluates the efficacy, safety and tolerability of NER1006 versus MOVIPREP in adult patients requiring bowel cleansing prior to any procedure that requires a clean bowel, using a 2-Day evening/morning Split-Dosing and 1-Day morning only Split-Dosing regimens. Approximately 810 patients will be randomised with the aim of achieving a minimum of 245 patients in each of the 3 groups.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colon Cleansing
- Being tested
- NER1006, 2-Day Split-Dosing, NER1006,1-Day Morning Split-Dosing, MOVIPREP, 2-Day Split-Dosing
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NER1006, 2-Day Split-DosingDrug
The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
NER1006,1-Day Morning Split-DosingDrug
The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.
After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid.
MOVIPREP, 2-Day Split-DosingDrug
The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
| Study group | Role | What they receive |
|---|---|---|
| NER1006, 2-Day Split-Dosing | Experimental | NER1006: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy). Receives: Drug: NER1006, 2-Day Split-Dosing |
| NER1006,1-Day Morning Split-Dosing | Experimental | NER1006: 1-Day Morning Split-Dosing Regimen (to commence in the morning of the day of colonoscopy). Receives: Drug: NER1006,1-Day Morning Split-Dosing |
| MOVIPREP, 2-Day Split-Dosing | Active comparator | MOVIPREP®: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy). Receives: Drug: MOVIPREP, 2-Day Split-Dosing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Patients With Successful Bowel Cleansing (Overall Colon)
The overall quality of bowel cleansing was assessed by a blinded central reader (an experienced and trained colonoscopist) using the segmental scores of the Harefield Cleansing Scale (HCS). A final HCS grading of A, B, C or D was derived. Grades A and B are classified as successful (i.e. all mucosa could be visualized) and C and D are classified as unsuccessful. Comparison of overall success of cleansing with NER1006 2-Day and 1-Day versus MOVIPREP was evaluated using a non-inferiority study design.
Measured: Up to 2 days (from day of first dosing to day of colonoscopy)
Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens)
The overall quality of bowel cleansing was assessed by a blinded central reader (an experienced and trained colonoscopist) using the segmental scores of the Harefield Cleansing Scale (HCS). Highly effective cleansing in the colon ascendens corresponded to scores 3 (Good) or 4 (Excellent) of the HCS. Adequate plus failure of cleansing corresponded to score 0-2. Comparison of 'Excellent plus good' cleansing of the colon ascendens using NER1006 2-Day and 1-Day versus MOVIPREP was evaluated using a non-inferiority study design.
Measured: Up to 2 days (from day of first dosing to day of colonoscopy)
Secondary outcomes (4)
Adenoma Detection Rate (Colon Ascendens)
Comparison of the number of patients with at least one adenoma detected in the colon ascendens when NER1006 2-Day and 1-Day is used for bowel cleansing versus MOVIPREP. Adenoma detection rate (ADR) defined as the number of patients with at least one adenoma in the colon ascendens.
Measured: Up to 2 days (from day of first dosing to day of colonoscopy)
Adenoma Detection Rate (Overall Colon)
Comparison of the number of patients with at least one adenoma detected in the overall colon when NER1006 2-Day and 1-Day is used for bowel cleansing versus MOVIPREP. Adenoma detection rate (ADR) defined as the number of patients with at least one adenoma in the overall colon.
Measured: Up to 2 days (from day of first dosing to day of colonoscopy)
Polyp Detection Rate (Colon Ascendens)
Comparison of the number of patients with at least one polyp detected in the colon ascendens when NER1006 2-Day and 1-Day is used for bowel cleansing versus MOVIPREP. Polyp detection rate (PDR) defined as the number of patients with at least one polyp in the colon ascendens.
Measured: Up to 2 days (from day of first dosing to day of colonoscopy)
Polyp Detection Rate (Overall Colon)
Comparison of the number of patients with at least one polyp detected in the overall colon when NER1006 is used for bowel cleansing versus number detected when MOVIPREP is used. PDR defined as the number of patients with at least one polyp in the overall colon.
Measured: Up to 2 days (from day of first dosing to day of colonoscopy)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2014 (estimated)
- Study startOct 2014
- Primary completionAug 2015
- Study completionAug 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 849 participants (actual)
Sponsor and investigators
- Lead sponsor
- Norgine
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Raf Bisschops, MD, Principal investigator, UZ Leuven
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02273167
- Sponsor's protocol ID
- NER1006-02/2014 (MORA)
- Acronym
- MORA
- Status last verified
- Apr 2018
- First submitted
- 16 Oct 2014
- Last updated
- 15 May 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Cash BD, Allen C, Poppers DM. Transient alterations in plasma sodium concentrations with NER1006 bowel preparation: an analysis of three phase III, randomized clinical trials. BMC Gastroenterol. 2022 Sep 5;22(1):412. doi: 10.1186/s12876-022-02484-7.
PubMed 36064325Bisschops R, Manning J, Clayton LB, Ng Kwet Shing R, Alvarez-Gonzalez M; MORA Study Group. Colon cleansing efficacy and safety with 1 L NER1006 versus 2 L polyethylene glycol + ascorbate: a randomized phase 3 trial. Endoscopy. 2019 Jan;51(1):60-72. doi: 10.1055/a-0638-8125. Epub 2018 Jul 19.
PubMed 30025414
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) Versus MOVIPREP Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.
- ClinicalTrials.gov ID
- NCT02273167
- Acronym / sponsor ID
- MORA / NER1006-02/2014 (MORA)
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colon Cleansing
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 849 participants (actual)
- Lead sponsor
- NorgineIndustry (pharma, biotech, devices)
- Study start
- Oct 2014
- Primary completion
- Aug 2015 (actual)
- Study completion
- Aug 2015 (actual)
- First posted
- 23 Oct 2014 (estimated)
- Results
- Posted 18 Apr 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the efficacy, safety and tolerability of NER1006 versus MOVIPREP in adult patients requiring bowel cleansing prior to any procedure that requires a clean bowel, using a 2-Day evening/morning Split-Dosing and 1-Day morning only Split-Dosing regimens. Approximately 810 patients will be randomised with the aim of achieving a minimum of 245 patients in each of the 3 groups.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| NER1006, 2-Day Split-Dosing | Experimental | Drug: NER1006, 2-Day Split-DosingNER1006: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy). |
| NER1006,1-Day Morning Split-Dosing | Experimental | Drug: NER1006,1-Day Morning Split-DosingNER1006: 1-Day Morning Split-Dosing Regimen (to commence in the morning of the day of colonoscopy). |
| MOVIPREP, 2-Day Split-Dosing | Active comparator | Drug: MOVIPREP, 2-Day Split-DosingMOVIPREP®: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy). |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients must provide written informed consent.
- Male and female outpatients and inpatients aged: ≥18 to ≤85 years undergoing a screening, surveillance or diagnostic colonoscopy.
- Females of child-bearing potential must have a negative pregnancy test at Screening and at Visit 2 and must be practising one of the following methods of birth control and agree to continue with the regimen throughout the study period (unless postmenopausal or surgically sterile, or whose sole sexual partner has had a successful vasectomy): Oral, implantable, or injectable contraceptives (for a minimum of three months before study entry) in combination with a condom; Intrauterine device in combination with a condom; Double barrier method (condom* and occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam/gel/film/cream/suppository).
- Willing and able to complete the entire study and to comply with instructions.
Key exclusion criteria (24 listed)
- Patients with past history within last 12 months or current episode of severe constipation (requiring repeated use of laxatives/enema or physical intervention before resolution), known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.
- Patients with ongoing severe acute Inflammatory Bowel Disease.
- Patients who have had previous significant gastrointestinal surgeries, including colonic resection, sub-total colectomy, abdomino-perineal resection, de-functioning colostomy, Hartmann's procedure and de-functioning ileostomy or other similar surgeries involving structure and function of the small or large colon.
- Regular use of laxatives or colon motility altering drugs in the last month (i.e. more than 2-3 times per week) and/or laxative use within 72 hours prior to administration of the preparation.
- Patients with active intestinal bleeding episodes or with a clinically significant low hemoglobin level <9 g/dL for women and <11 g/dL for men at screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NER1006, 2-Day Split-DosingThe subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy. | Drug | NER1006, 2-Day Split-Dosing |
| NER1006,1-Day Morning Split-DosingThe subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid. After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid. | Drug | NER1006,1-Day Morning Split-Dosing |
| MOVIPREP, 2-Day Split-DosingThe subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy. | Drug | MOVIPREP, 2-Day Split-Dosing |
Primary outcome
Number of Patients With Successful Bowel Cleansing (Overall Colon)
Time frame: Up to 2 days (from day of first dosing to day of colonoscopy)
The overall quality of bowel cleansing was assessed by a blinded central reader (an experienced and trained colonoscopist) using the segmental scores of the Harefield Cleansing Scale (HCS). A final HCS grading of A, B, C or D was derived. Grades A and B are classified as successful (i.e. all mucosa could be visualized) and C and D are classified as unsuccessful. Comparison of overall success of cleansing with NER1006 2-Day and 1-Day versus MOVIPREP was evaluated using a non-inferiority study design.
Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens)
Time frame: Up to 2 days (from day of first dosing to day of colonoscopy)
The overall quality of bowel cleansing was assessed by a blinded central reader (an experienced and trained colonoscopist) using the segmental scores of the Harefield Cleansing Scale (HCS). Highly effective cleansing in the colon ascendens corresponded to scores 3 (Good) or 4 (Excellent) of the HCS. Adequate plus failure of cleansing corresponded to score 0-2. Comparison of 'Excellent plus good' cleansing of the colon ascendens using NER1006 2-Day and 1-Day versus MOVIPREP was evaluated using a non-inferiority study design.
4 secondary outcomes
Adenoma Detection Rate (Colon Ascendens)
Time frame: Up to 2 days (from day of first dosing to day of colonoscopy)
Adenoma Detection Rate (Overall Colon)
Time frame: Up to 2 days (from day of first dosing to day of colonoscopy)
Polyp Detection Rate (Colon Ascendens)
Time frame: Up to 2 days (from day of first dosing to day of colonoscopy)
Polyp Detection Rate (Overall Colon)
Time frame: Up to 2 days (from day of first dosing to day of colonoscopy)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 36064325Cash BD, Allen C, Poppers DM. Transient alterations in plasma sodium concentrations with NER1006 bowel preparation: an analysis of three phase III, randomized clinical trials. BMC Gastroenterol. 2022 Sep 5;22(1):412. doi: 10.1186/s12876-022-02484-7.
- Derived from this study: PubMed 30025414Bisschops R, Manning J, Clayton LB, Ng Kwet Shing R, Alvarez-Gonzalez M; MORA Study Group. Colon cleansing efficacy and safety with 1 L NER1006 versus 2 L polyethylene glycol + ascorbate: a randomized phase 3 trial. Endoscopy. 2019 Jan;51(1):60-72. doi: 10.1055/a-0638-8125. Epub 2018 Jul 19.
- Individual participant dataSharing planned: No
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
Colorectal Cancer (CRC)
Not yet recruiting
FLuorescent Angiography in REduction of Anastomotic Leak in Rectal Cancer Surgery
Rectal Cancer Patients, Rectal Cancer Surgery
Not yet recruiting
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
Not yet recruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Raf Bisschops, MD principal investigator
UZ Leuven
29 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing NER1006, 2-Day Split-Dosing, NER1006,1-Day Morning Split-Dosing and MOVIPREP, 2-Day Split-Dosing in people with Colorectal Cancer and Colorectal Carcinoma, run by Norgine at 29 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 May 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 29 sites in Poland, Italy, Spain, Belgium, United Kingdom and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 18 Apr 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Patients With Successful Bowel Cleansing (Overall Colon) (time frame: Up to 2 days (from day of first dosing to day of colonoscopy)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02273167, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2018.